Article

Quality by Design Based Formulation and Development of a Novel Bi-Compound Pharmaceutical Capsule: An Innovative Approach for the Treatment of Hypertension

Aiman Rabiya1★, Mohamed Hassan Dehghan1★★ Corresponding author

  1. 1Department of Pharmaceutics, Y. B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Rauza Bagh, Aurangabad, Maharashtra, INDIA.

CORRESPONDENCE

Aiman Rabiya

Department of Pharmaceutics, Y.B. Chavan College of Pharmacy, Post Box No. 33, Dr. Rafiq Zakaria Campus, Rauza Bagh, Aurangabad-431001, Maharashtra, INDIA.

aimanrabiya@gmail.com

Received: 28-01-2025; Revised: 09-04-2025; Accepted: 18-06-2025.

Volume 59, Issue 3S · pp. s890–s901 · PUBLISHED Jul-Sep 2025 · DOI: 10.5530/ijper.20252275

View on IJPER original site ↗

ABSTRACT

Objectives: This study aimed to develop a novel bi-compound pharmaceutical capsule containing nifedipine gastro-retentive floating microspheres and telmisartan immediate-release solid dispersions using a Quality by Design (QbD) approach. Materials and Methods: QbD methodology was applied to optimize the formulations and ensure product quality. Risk assessment tools identified the Critical Material Attributes (CMA) and Critical Process Parameters (CPP). A Plackett-Burman screening design was applied to examine the impact of these factors on Critical Quality Attributes (CQA), followed by a Box-Behnken optimization design to establish the design space. The optimized formulation was analyzed, and drug-excipient compatibility was confirmed using FTIR, DSC, and XRD analyses. Results and Discussion: The results demonstrated that the optimized nifedipine microspheres remained buoyant for over 12 hr with 95.15% drug release at 12 hr. Telmisartan solid dispersions exhibited 97.83% drug release within 1 hr. Particle size analysis revealed the size range of 200-300 μm for bi-compound pharmaceutical formulation. The drug entrapment efficiency was 80-90% for both components. In vivo gamma scintigraphy in rats confirmed the gastro-retentive properties over 12 hr. Stability studies demonstrated <5% change in critical quality attributes over 12 months of storage, confirming the robustness of this formulation. Conclusion: The QbD-guided development of this bi-compound pharmaceutical capsule presents a promising approach for effective hypertension management, with the potential for improved patient compliance and therapeutic outcomes.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Rabiya, A., & Dehghan, M. H. (2025). Quality by Design Based Formulation and Development of a Novel Bi-Compound Pharmaceutical Capsule: An Innovative Approach for the Treatment of Hypertension. Indian Journal of Pharmaceutical Education and Research, 59(3S), s890–s901. https://doi.org/10.5530/ijper.20252275